Key Highlights
● Stark Focus Group's board unanimously approved hiring Matthew Szot as Chief Financial Officer effective October 8, 2026, with CEO John Lipman stepping back from the CFO role he had also been holding.
● Szot's compensation includes a $450,000 annual base salary, a cash Bonus targeted at 50% of base salary, and, starting in 2027, long-term incentive awards valued between 50% and 75% of his base salary each year.
● The headline feature is a $200,000 award of Fully Vested common stock payable when the company completes its planned Nasdaq listing, or paid in cash instead if his employment ends within six months of his start date but before the listing.
● Szot, 52, currently serves as Chairman of SenesTech, Inc. (Nasdaq: SNES) and as CFO of Cadrenal Therapeutics, with earlier CFO experience at S&W Seed Company from 2010 to 2021.
Stark Focus Group, Inc. (OTC:SKFG) disclosed in an 8-K that its board unanimously approved hiring Matthew Szot as Chief Financial Officer, effective October 8, 2026, with compensation structured to reward him if the company succeeds in its stated goal of uplisting to the Nasdaq exchange.
The Hire and Reporting Structure
Szot, 52, will report directly to CEO John Lipman, who is transitioning out of the CFO role he had also been holding to focus solely on his duties as Chief Executive Officer and director. The board approved the appointment on September 21, 2026, and the employment agreement, filed as Exhibit 10.1, runs for an initial one-year term that automatically renews unless either side gives 60 days' notice.
Pay Tied to the Uplisting
The compensation package layers a $450,000 annual base salary, subject to future increases on annual review, with an annual cash bonus targeted at 50% of base salary contingent on performance targets the board will set. Starting in 2027, Szot becomes eligible for long-term incentive awards valued between 50% and 75% of his base salary each year.
The headline feature tied to Stark Focus Group's Nasdaq ambitions is a $200,000 award of fully vested common stock, payable when the company completes its planned Nasdaq listing. If Szot's employment ends before that listing happens, but within six months of his start date, the filing says he would instead receive that $200,000 in cash, a provision that effectively guarantees the payment regardless of listing timing within that window.
Employment Protections and Background
The agreement carries a six-month probationary period during which either party can terminate for any reason, with Szot entitled to four weeks of severance if let go during that stretch. After probation, a termination without cause or a resignation for good reason entitles him to three months of salary plus any earned bonus, along with acceleration of outstanding Equity awards.
Szot brings a lengthy resume in small-cap finance leadership. He currently serves as Chairman of SenesTech, Inc. (Nasdaq: SNES) since May 2026 and as CFO of Cadrenal Therapeutics since May 2022. His earlier CFO stint at S&W Seed Company ran from 2010 to 2021, and he has also held board seats at INVO Fertility and Eastside Distilling, plus CFO roles at Cardiff Partners and Rip Curl. He is a licensed CPA and holds a degree from the University of Illinois.
What the Filing Leaves Open
The 8-K does not state a target date for the Nasdaq uplisting itself, nor does it describe what listing standards, share price, market capitalization, public float, the company still needs to satisfy. It also does not disclose the size of Lipman's compensation adjustment, if any, now that he has shed the CFO title, or whether Stark Focus Group has retained any advisers to manage the uplisting process. The filing does not identify the exchange tier (Global Market, Capital Market, or Global Select Market) the company is targeting, and it does not restate Stark Focus Group's core Business beyond identifying it as an OTC-quoted issuer currently reporting under Exchange Act rules.
Because Stark Focus Group trades over the counter today, an uplisting would move its shares onto a national securities exchange, typically subjecting the company to stricter corporate-governance, financial-reporting and minimum-share-price requirements than OTC trading demands. The 8-K does not say whether the company has begun the formal listing application process with Nasdaq or is still preparing to meet initial listing thresholds.
Milestones on the Path to a Nasdaq Listing
Key items flagged by the filing include October 8, 2026, Szot's official start date as CFO; the six-month mark from his hire date, which is the outer boundary for the cash-in-lieu provision tied to the stock award; and any future 8-K disclosing formal application to, or approval by, Nasdaq, which would trigger the $200,000 equity award described in his contract.




_11_17_2026_20_39_10_193219.jpg)

Please wait processing your request...